IPP Bureau
RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects
By IPP Bureau - January 06, 2026
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
PathoCare Holdings valued at $1.75 billion following major third-party tender offer
By IPP Bureau - January 06, 2026
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Nia Therapeutics unveils first implantable brain interface for memory disorders
By IPP Bureau - January 06, 2026
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Singapore clears AI bladder cancer detection tool
By IPP Bureau - January 06, 2026
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
By IPP Bureau - January 06, 2026
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva and Serum Institute end chikungunya vaccine partnership
By IPP Bureau - January 06, 2026
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
By IPP Bureau - January 06, 2026
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Abbott unveils Libre Assist to help meal management in diabetics
By IPP Bureau - January 06, 2026
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
Jaguar Health wins $240,000 FDA grant to advance dog cancer diarrhea treatment
By IPP Bureau - January 05, 2026
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
By IPP Bureau - January 05, 2026
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
FDA delays Corcept’s hypertension drug, seeks more evidence
By IPP Bureau - January 05, 2026
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
FDA flags uncertainty over PFAS in cosmetics, calls for more research
By IPP Bureau - January 05, 2026
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
Exports of AYUSH and herbal products touches US$ 689 million in 2024–25
By IPP Bureau - January 05, 2026
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Indian Vice President calls for global recognition of traditional medicine
By IPP Bureau - January 05, 2026
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
FibroBiologics moves experimental psoriasis therapy into FDA review
By IPP Bureau - January 04, 2026
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
